Preeclampsia complicates 5-7% of all pregnancies and is a major cause of maternal and perinatal morbidity and mortality worldwide. Aberrant expression of angiogenic modulators is important in the pathogenesis of preeclampsia. Studies have shown that maternal circulating levels of placenta-derived anti-angiogenic proteins such as a shortened endoglin (sENG) and soluble fms-like tyrosine kinase 1 receptor (sFLT1) are significantly higher in pregnancies complicated by preeclampsia than in normotensive control pregnancies. The precise mechanism(s) responsible for processing and shedding of these anti-angiogenic factors by the syncytiotrophoblast (ST) layer and their mode of transport in the maternal circulation remains elusive. Therefore, we ha...
BACKGROUND: Differences in circulating concentrations of antiangiogenic factors sFlt1 and soluble en...
BACKGROUND: Alterations in circulating soluble fms-like tyrosine kinase 1 (sFlt1), an antiangiogenic...
In preeclampsia, the antiangiogenic factor soluble fms-like tyrosine kinase-1 (sFLT-1) is released f...
Preeclampsia complicates 5-7% of all pregnancies and is a major cause of maternal and perinatal morb...
Preeclampsia complicates 5-7% of all pregnancies and is a major cause of maternal and perinatal morb...
Preeclampsia has increased circulating levels of a short form of the auxillary TGF-beta (TGFB) recep...
Preeclampsia has increased circulating levels of a short form of the auxillary TGF-beta (TGFB) recep...
Preeclampsia has increased circulating levels of a short form of the auxillary TGF-beta (TGFB) recep...
The pathogenesis of pre-eclampsia is biphasic. The first phase is characterised by insufficient plac...
Preeclampsia (PE), an hypertensive disorder of pregnancy, exhibits increased circulating levels of a...
Imbalanced signaling between maternal and placental cells contributes to preeclampsia, suggests a ne...
Differences in circulating concentrations of antiangiogenic factors sFlt1 and soluble endoglin (sEng...
textabstractThe pathogenesis of pre-eclampsia is biphasic. The first phase is characterised by insuf...
Differences in circulating concentrations of antiangiogenic factors sFlt1 and soluble endoglin (sEng...
Differences in circulating concentrations of antiangiogenic factors sFlt1 and soluble endoglin (sEng...
BACKGROUND: Differences in circulating concentrations of antiangiogenic factors sFlt1 and soluble en...
BACKGROUND: Alterations in circulating soluble fms-like tyrosine kinase 1 (sFlt1), an antiangiogenic...
In preeclampsia, the antiangiogenic factor soluble fms-like tyrosine kinase-1 (sFLT-1) is released f...
Preeclampsia complicates 5-7% of all pregnancies and is a major cause of maternal and perinatal morb...
Preeclampsia complicates 5-7% of all pregnancies and is a major cause of maternal and perinatal morb...
Preeclampsia has increased circulating levels of a short form of the auxillary TGF-beta (TGFB) recep...
Preeclampsia has increased circulating levels of a short form of the auxillary TGF-beta (TGFB) recep...
Preeclampsia has increased circulating levels of a short form of the auxillary TGF-beta (TGFB) recep...
The pathogenesis of pre-eclampsia is biphasic. The first phase is characterised by insufficient plac...
Preeclampsia (PE), an hypertensive disorder of pregnancy, exhibits increased circulating levels of a...
Imbalanced signaling between maternal and placental cells contributes to preeclampsia, suggests a ne...
Differences in circulating concentrations of antiangiogenic factors sFlt1 and soluble endoglin (sEng...
textabstractThe pathogenesis of pre-eclampsia is biphasic. The first phase is characterised by insuf...
Differences in circulating concentrations of antiangiogenic factors sFlt1 and soluble endoglin (sEng...
Differences in circulating concentrations of antiangiogenic factors sFlt1 and soluble endoglin (sEng...
BACKGROUND: Differences in circulating concentrations of antiangiogenic factors sFlt1 and soluble en...
BACKGROUND: Alterations in circulating soluble fms-like tyrosine kinase 1 (sFlt1), an antiangiogenic...
In preeclampsia, the antiangiogenic factor soluble fms-like tyrosine kinase-1 (sFLT-1) is released f...